Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. trimmed its position in Hologic, Inc. (NASDAQ:HOLX) by 8.1% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,555,211 shares of the medical equipment provider’s stock after selling 226,514 shares during the period. Alliancebernstein L.P. owned 1.13% of Hologic worth $184,205,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brooklyn Investment Group lifted its position in Hologic by 14.7% during the fourth quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares during the period. Smartleaf Asset Management LLC lifted its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the period. Trivant Custom Portfolio Group LLC boosted its stake in shares of Hologic by 2.1% in the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock worth $602,000 after buying an additional 169 shares during the last quarter. UMB Bank n.a. grew its holdings in Hologic by 4.1% during the fourth quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider’s stock worth $343,000 after acquiring an additional 188 shares during the period. Finally, Capital Investment Counsel Inc raised its position in Hologic by 3.6% during the fourth quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider’s stock valued at $413,000 after acquiring an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $61.38 on Wednesday. The company has a market cap of $13.77 billion, a P/E ratio of 19.36, a P/E/G ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The company’s 50-day moving average price is $64.90 and its 200-day moving average price is $72.97. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. On average, sell-side analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on HOLX. BNP Paribas upgraded Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 6th. Leerink Partners cut shares of Hologic from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Argus lowered shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Wolfe Research started coverage on Hologic in a research note on Friday, December 13th. They issued a “peer perform” rating for the company. Eleven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Hologic has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.